Lansoprazol

Lansoprazole, the active ingredient in Lansoprazol, is a proton pump inhibitor presented as an oral tablet for oral use. It suppresses gastric acid production and is used to treat acid‑related disorders such as gastro‑oesophageal reflux disease, erosive esophagitis and peptic ulcer disease in adult patients.

GNH USA supplies Lansoprazol as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides reliable global distribution to meet clinical demand worldwide consistently.

Lansoprazole is indicated for several acid‑related conditions, acting on the gastric proton pump to reduce acid secretion.

- Gastroesophageal reflux disease (GERD): reduces esophageal acid exposure, relieving heartburn and regurgitation. - Erosive esophagitis: promotes healing of damaged esophageal mucosa by maintaining a higher gastric pH. - Peptic ulcer disease: facilitates ulcer healing and prevents recurrence by suppressing gastric acid production.

Lansoprazole may be associated with a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Headache: mild to moderate pain often transient. - Diarrhea: loose stools that may resolve with continued therapy. - Nausea: feeling of sickness without vomiting. - Abdominal pain: discomfort in the stomach area.

Serious or Rare Side Effects: - Clostridioides difficile infection: severe colitis requiring medical attention. - Acute interstitial nephritis: kidney inflammation presenting with fever and rash. - Stevens‑Johnson syndrome: rare skin reaction with blistering and mucosal involvement.

Before prescribing Lansoprazole, clinicians should consider several safety considerations and patient‑specific factors. - Assess renal function: dose adjustment may be needed in severe impairment. - Evaluate hepatic status: use with caution in patients with liver disease. - Review concomitant medications: potential for drug‑drug interactions, especially with antiplatelet agents. - Monitor for infection risk: prolonged acid suppression can increase susceptibility to gastrointestinal infections. - Counsel on long‑term use: extended therapy may be linked to vitamin B12 deficiency or bone fracture risk. - Store at ambient temperature: keep below 25 °C, in the original container, protected from moisture and light.

Lansoprazole can alter the plasma concentrations of several co‑administered drugs, requiring attention to interaction severity.

Major Interactions (Avoid): - Clopidogrel: reduced antiplatelet effect, may increase cardiovascular risk. - Atazanavir: decreased antiviral absorption, compromising HIV therapy. - Dasatinib: lowered exposure, reducing oncologic efficacy.

Moderate Interactions (Monitor Closely): - Warfarin: enhanced anticoagulant effect, monitor INR. - Methotrexate: increased serum levels, watch for toxicity. - Digoxin: modest increase in concentration, assess clinical response.